Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CFD | P00746 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20488805 | 0.93 | KDM4E (0.33) | KDM4ECFDPTPN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29855040 | 0.89 | MTNR1A (0.30) | — | |
| SCHEMBL25940586 | 0.88 | NPC1 (0.32) | KDM4EPTPN1NPC1MITFS1PR4 | |
| SCHEMBL25940585 | 0.83 | CFD (0.35) | CFD | |
| SCHEMBL20488397 | 0.79 | KDM4E (0.33) | KDM4EPTPN1ALDH1A1 | |
| SCHEMBL20488318 | 0.76 | CFD (0.35) | CFD | |
| SCHEMBL29855221 | 0.76 | KDM4E (0.33) | KDM4EPTPN1ALDH1A1 | |
| SCHEMBL29855036 | 0.73 | CFD (0.33) | CFD | |
| SCHEMBL25940616 | 0.71 | ALDH1A1 (0.38) | KDM4ECFDALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL31373439 | 0.69 | KDM4E (0.37) | KDM4EPTPN1NPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | KDM4E 3629/4885CFD 1/4885PTPN1 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.